anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Chronic hepatitis B (CHB) is well-known as a major risk for liver cirrhosis and hepatocellular carcinoma (HCC). The A1762T/G1764A double mutation in the hepatitis B virus genome affects the production of HBe antigen and is established as a predictive marker for progression to HCC. Thus, this study aimed to investigate the prevalence and clinical significance of the mutation in Thai CHB patients.
METHODS: A cross-sectional study was conducted in 78 Thai CHB patients who were assessed for hepatitis B profiles, HBsAg, HBeAg and anti-HBeAg, transaminitis, liver fibrosis defined by FIB-4 (FIB-4) score and AST to platelet ratio index (APRI), alpha-fetoprotein (AFP) and active hepatitis B status. HBV A1762T/G1764A mutation was examined by SYBR Green I Real-time PCR. Chi-square and Mann-Whiney U tests were performed to determine the association between the mutation and variables.
RESULTS: The prevalence of patients infected with the A1762T/G1764A mutation was 44.9%. The mutation was associated with HBeAg status (p=0.027) and HBsAg levels (p=0.008), transaminitis (p=0.011), and active hepatitis B (p=0.037), but not liver fibrosis markers, FIB-4 score and APRI, and AFP. Binary logistic regression identified the mutation as a predictive factor of active hepatitis B (OR 3.5, 95%CI, 1.1-11.3, p=0.037). Patients infected with the mutant exhibited significantly higher levels of HBsAg (p=0.011) and HBV viral load (p=0.047), but lower levels of HBeAg (p=0.12) than those infected with the wild-type HBV.
CONCLUSION: The data indicate the high prevalence of the A1762T/G1764A mutation and its significant association with the severity of Thai CHB patients and the HBV mutation is proposed as a predictive marker of active hepatitis B status in CHB patients.
Kidney transplantation is widely considered to be the treatment of choice for children with End Stage Renal Disease (ESRD). Improvements in surgical techniques, donor selection, and immunosuppression practices, as well as the enhanced experience of specialized pediatric transplant teams, have all led to marked improvements in patient and kidney graft survival in infants and young children ages 1 to 10. However, young children now have more infections following transplant previously. Also, improved graft survival is not observed in pediatric renal transplant recipients 11 to 17 years of age. Some studies do indicate that the poor long term outcome of patient and kidney survival observed in this age group may be caused by noncompliance with immunosuppressive medications. Therefore, protocols that minimize the use of immunosuppressive medications while retaining kidney function are necessary for improving graft and patient survival in children. This study will evaluate the safety of a regimen containing alemtuzumab after kidney transplantation, followed by steroid avoidance and calcineurin inhibitor withdrawal in pediatric renal transplant recipients 1 to 20 years of age.

The accrual period is scheduled for 18 months. The study follow-up period will last 24 months. All participants enrolled will undergo this treatment schedule: 1.) All participants will receive intravenous alemtuzumab one day before transplantation and 1 day after transplantation. 2.) Mycophenolate mofetil (MMF) will be administered orally no later than 2 days after transplantation. 3.) Participants will begin to take oral tacrolimus twice a day 1 to 3 days after transplantation until Weeks 8 through 12 when 4.) Sirolimus will be initiated. 5.) Sirolimus and MMF will be taken orally until Month 24.

Blood collection will occur at baseline, 1 day before transplant, at Days 1 and 3, at Weeks 2, 4, 6, 8, 10, and at Months 3 through 24. Scheduled kidney (renal) biopsies will be performed at transplant, during Weeks 8 through 12, immediately before conversion to sirolimus, and at Months 6 and 24.
Cochlear hair cells (HCs) sense sound waves and allow us to hear. Loss of HCs will cause irreversible sensorineural hearing loss. It is well known that DNA damage repair plays a critical role in protecting cells in many organs. However, how HCs respond to DNA damage and how defective DNA damage repair contributes to hearing loss remain elusive. In this study, we showed that cisplatin induced DNA damage in outer hair cells (OHCs) and promoted OHC loss, leading to hearing loss in mice of either sex. Cisplatin induced the expression of Brca1, a DNA damage repair factor, in OHCs. Deficiency of Brca1 induced OHC and hearing loss, and further promoted cisplatin-induced DNA damage in OHCs, accelerating OHC loss. This study provides the first in vivo evidence demonstrating that cisplatin mainly induces DNA damage in OHCs and that BRCA1 promotes repair of DNA damage in OHCs and prevents hearing loss. Our findings not only demonstrate that DNA damage-inducing agent generates DNA damage in postmitotic HCs but also suggest that DNA repair factors, like BRCA1, protect postmitotic HCs from DNA damage-induced cell death and hearing loss.
FIELD: diagnostic methods in medicine. SUBSTANCE: agent for ultrasonic diagnostics contains microparticles consisting of mixture of at least one saturated C 12 -C 16 -fatty acid with galactose and a component gaseous at body temperature: perfluoropropane, perfluobutane, hexafluoroethane, or their mixture. Ultrasonic contrast means contains above-indicated agent suspended in a physiologically acceptable liquid suspension medium with, if necessary, conventional additives utilized in pharmaceutical technology. Ultrasonic contrast means preparation kit and a method for preparing above ultrasonic diagnostics agent are also available. EFFECT: enabled durable contrast effect in blood visualizing blood flow conditions in left and right heart sides. 7 cl, 2 tbl, 19 ex
<P>PROBLEM TO BE SOLVED: To provide a new and safe hyaluronidase activity inhibitor and a cosmetic composition.   <P>SOLUTION: The hyaluronidase activity inhibitor and cosmetic component are provided by containing 1 kind or ≥2 kinds selected from grape fruit, Japanese pepper and Chinese milk vetch and have the hyaluronidase inhibitory activity for imparting tension and bloom to a skin, and improving wrinkles and sag of the skin. Further, it is possible to improve inflammatory skin diseases (e.g. eczema, an itch, skin roughness, etc.). Therefore it is effective for the prevention of skin aging or dermatitis.  <P>COPYRIGHT: (C)2004,JPO
The increased prevalence of obesity among the children of military personnel has paralleled that observed in the civilian population. Disordered eating, especially binge or loss of control (LOC) eating, is common among adolescents and is a salient risk factor for obesity and the development of exacerbated disordered eating and depressive symptoms. The goal of this study is to test the effectiveness of interpersonal psychotherapy (IPT) to slow the trajectory of weight gain in adolescent girls at high-risk for adult obesity by virtue of elevated body mass index (BMI) percentile and LOC eating. IPT targets the difficult social functioning and stressful events that are associated with LOC and highly relevant to the adolescent youth from military families. Adolescent military dependents will be randomized to receive either the IPT weight gain prevention program or a health education (HE) control condition, for 12 weekly group sessions. Adolescents' weight status, eating behaviors, and mood will be assessed at baseline, immediately following the prevention program (12-weeks), and at 1-year follow-up. At 2-year and 3-year follow-up time points, participants' BMI and physiologic data will be collected via the Military Health System's electronic medical record system. It is hypothesized that adolescents who receive the IPT group program will show significantly less weight gain (or more weight loss) relative to those randomized to HE at 3-year follow-up. Additionally, it is hypothesized that adolescents receiving IPT (as compared to HE) will demonstrate improvements on secondary outcomes of interest, including the presence and frequency of classic binge eating episodes, as well as obesity-related physiological measures of health (e.g., fasting insulin). The overall goal of the study is to prevent excess weight gain and adult obesity, and to prevent worsening disordered eating and metabolic functioning among overweight military dependents at risk for adult obesity and binge eating disorders.
The invention discloses foot odor preventing medical powder which is prepared by mixing and crushing raw materials into powder. The foot odor preventing medical powder comprises the following materials in percentage by weight: 75 to 100 percent of sodium bicarbonate, 0 to 22 percent of metronidazole, and 0 to 2.4 percent of thiamine hydrochloride and 0 to 0.6 percent of chlorphenamine maleate which are prepared into powder by mixing. The further improved scheme of the invention comprises the following materials in percentage by weight: 80 to 95 percent of sodium bicarbonate, 4.3 to 17 percent of metronidazole, 0.5 to 2.4 percent of thiamine hydrochloride and 0.2 to 0.6 percent of chlorphenamine maleate. The medical materials of the medical powder can mutually promote, complement and cooperate, and have remarkable effects on barbier and remarkable deodorization effects on shoes and feet. The medical powder is non-toxic and armless to human body, and has no incitement to skin of human. The medical powder can be used by the old, children and pregnant women.
BACKGROUND/AIM: This study aimed to investigate the influence of Western diet on mammary cancer in Wistar female rats, focusing on systemic responses and tumor development.
MATERIALS AND METHODS: Twenty-eight Wistar female rats were acclimatized and divided into four experimental groups (n=7 each): Western diet (WD), Western diet with N-methyl-N-nitrosourea (MNU) administration (WD+MNU), standard diet (CTR), and standard diet with MNU administration (CTR+MNU). MNU was administered intraperitoneally at 50 mg/kg at seven weeks of age to induce mammary cancer. The 20-week experiment involved monitoring animal weight, food and water intake. At the end of the study, rats were euthanized, and blood samples and organs were collected for hematological and plasma biochemical analysis, oxidative stress, and histo-pathological and immunobiological evaluations of the tumors.
RESULTS: No significant differences were found in body weight, composition, or organ weights, but the WD group showed reduced food and water intake and lower cholesterol levels. Leptin and adiponectin levels were higher in the WD+MNU group, suggestive of changes in appetite regulation. Histopathological analysis showed malignant tumors in both MNU-induced groups. However, WD groups had fewer tumors compared to the CTR+MNU group.
CONCLUSION: WD led to higher feed efficiency and increased visceral adipose tissue but decreased systemic cholesterol and triglyceride levels. While this diet resulted in lower tumor incidence, the volume and weight of the tumors were higher. Additionally, the WD decreased ERα and progesterone receptor immunoexpression, while Ki-67 immunoexpression was elevated.
PURPOSE:To provide a radioactive diagnostic agent labeled with radioactive metal, and useful for the nucleus medical use mainly for the determination of the figure and the function of various organs, by contacting a non-radioactive composition containing a thiosemicarbazone derivative with a solution containing radioactive metallic ions. CONSTITUTION:The compound of formula IV (R, R' and R'' are H or 1-3C alkyl; n is 0-3) is mixed with a proper solvent in the presence or absence of a reducing agent (e.g. stannous salt) to obtain a composition useful for the preparation of a radioactive diagnostic agent. The objective radioactive diagnostic agent can be prepared by contacting the composition with a solution containing radioactive metallic ions (e.g. technetium-99m). The diagnostic agent is accumulated in the objective organ in high concentration within a short time. The compound of formula IV wherein R and R' are 1-3C alkyl can be prepared by introducing a propionyl group to the compound of formula I , reacting the product with isopropyl nitrite, and condensing the resultant compound of formula IIIwith the compound of formula V.
The invention relates to the field of a veterinary pharmaceutical and a feed additive, particularly relates to a production method of eupatorium (lindley eupatorium) clenbuterol powder and a granular formulation for preventing and treating respiratory diseases, namely a preparation method of eupatorium clenbuterol powder and the granular formulation. In the method, five Chinese medicinal crops, such as eupatorium and the like or decoction pieces and the like are taken as raw materials. The preparation method comprises the following steps: cutting the Chinese medicinal crops, such as eupatorium and the like into pieces; adding water; carrying out backflow extract; carrying out concentration, membrane separation or ordinary pressure concentration to obtain a concentrated solution; carrying out alcohol precipitation on the concentration solution or adding flocculant for clarification, membrane separation or resin absorption to remove ineffective components; concentrating, drying, smashing, adding a flavoring agent, an excipient or auxiliary materials composed by the flavoring agent and the excipient; and packaging. In the invention, the advantages of traditional Chinese medicine combination and a carrier or filler are combined; the process is optimized through experiments; the effective components of the traditional Chinese medicine are extracted completely, and the process is simple and feasible, and has easily controlled process. The formed product has no harmful residues, and is a safe and hormone-free green product. The preparation method provided by the invention is especially suitable for preventing and treating the respiratory diseases of livestock and poultry, and simultaneously also suitable for preventing and treating the respiratory diseases of animals, such as various pets and the like.
This study seeks to determine if modifying the hormonal milieu of the menstrual cycle, through administration of exogenous progesterone, will improve the effectiveness of treatments for smoking cessation in women. Progesterone, a gonadal hormone, is used clinically for treatment of endometrial hyperplasia, amenorrhea, dysfunctional uterine bleeding, and for assisted reproduction in women. Progesterone also shows promise for the treatment of multiple central nervous system disorders including cocaine addiction, seizure disorder, and traumatic brain injury. As the next step, the investigators seek to determine if progesterone augments standard smoking cessation treatments (e.g., NRT) in regularly cycling women. The investigators hypothesize that co-treatment with progesterone, compared to placebo, will enhance the effectiveness NRT for smoking cessation. To test this hypothesis, the investigators propose an 8-week, double-blind, placebo-controlled clinical trial, which will randomize 50 smokers using a 1:1 assignment ratio to 400 mg/day progesterone or placebo. Consistent with the Clinical Practice Guidelines, all participants will also receive transdermal nicotine patch (TNP) plus brief counseling for smoking cessation during the study participation.

Specific Aim #1: To determine if progesterone +TNP is superior to placebo +TNP for prolonged and 7-day point prevalence of smoking abstinence rates at the end of 8 weeks of treatment and at 1 and 3 month follow-up time points. The investigators will also evaluate the safety and tolerability of progesterone treatment, compared to placebo. Our co-primary outcome measures will be 7-day point prevalence of smoking abstinence and breath CO at the end of treatment and 1- and 3-months after the end of the trial. Specific Aim #2: To determine if progesterone + TNP treatment, compared to placebo + TNP, improves response inhibitory function, as assessed by the Stroop, The Go/No Go task, and the Digit Symbol Task. Specific Aim # 3: To determine if progesterone + TNP treatment, compared to placebo + TNP, leads to a greater reduction in cigarette craving and nicotine withdrawal symptoms, as assessed by the Questionnaire on Smoking Urges-Brief (QSU-B) and the Minnesota Nicotine Withdrawal Scale (MNWS), respectively. Specific Aim #4: To evaluate with affective changes, as shown on the Positive and Negative Affect Schedule, mediates the effects of progesterone on smoking abstinence.
Study Design:

This will be a Phase II, open-label, single-center, repeat dose, study. After a two-week screening phase, eligible subjects will receive combined docetaxel and erlotinib treatment over six cycles. Each 22-day treatment cycle will consist of two infusion of docetaxel, one-week apart followed by one week rest, and daily administration of erlotinib. Subjects, who complete six cycles of combination therapy, will continue receiving erlotinib monotherapy for as long as they are benefiting from this therapy in the opinion of the investigator (i.e. until continued toxicity or disease progression or withdrawal from the study). Subjects will be evaluated for safety and radiologic tumor assessment throughout the study until death. The study will be terminated after every living patient has had a follow up of at least 6 months after stopping TarcevaTM, or when all patients have died.
FIELD: medicine, therapy, pharmacy. SUBSTANCE: invention can be employed as an initial component for different medicinal agents preparing showing therapeutic effect. Also, the base of medicinal agent can be used as an independent medicinal agent showing high therapeutic effect. The base of proposed medicinal agent is placental material with liquid. Placental material with liquid is prepared as sour cream-like mass. Content and state of the sour cream-like mass is given in variants. EFFECT: improved quality, properties and effectiveness of agent, prolonged activity at storage.
For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 300-450 participants per year at each of five enrollment sites for evaluation of various novel TB triage and diagnostic tests and 50 health workers to assess test usability.
Primary glioma patients will receive perampanel along with their current AED for a total of 20 weeks. Perampanel will be titrated from 2 mg in weeks 1 and 2 and up to 8 mg daily by week 5 if well tolerated by the patient. They will then receive a maintenance dose of 8 mg per day through 16 weeks. After 16 weeks, subjects will be tapered off perampanel over a 4 week period.
To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.

Patients should be advised not to wear a contact lens if their eye is red. Olopatadine hydrochloride ophthalmic solution, 0.1% should not be used to treat contact lens related irritation. The preservative in olopatadine hydrochloride ophthalmic solution 0.1%, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least ten minutes after instilling olopatadine hydrochloride ophthalmic solution, 0.1% before they insert their contact lenses.
INTRODUCTION: Dalbavancin is an antibiotic active against most Gram-positive bacteria approved for acute bacterial skin and skin structure infections (ABSSSI). Owing to its long half-life, it is being increasingly used for other indications.
PATIENTS AND METHODS: We present a case series of children and adolescents treated with dalbavancin for osteoarticular, catheter-related and other non-ABSSSI infections.
RESULTS: Dalbavancin was prescribed to 15 patients. Six (40%) were female and median age at prescription was 11.9 (IQR 1.3-18.0) years. Most of them (12/15) had significant comorbidities. Patients presented mainly with deep surgical site infections, osteoarticular infections and central-line-associated bloodstream infections. The most common isolate was Staphylococcus aureus followed by Staphylococcus epidermidis. Major reasons to prescribe dalbavancin were to ensure compliance and patients' convenience. Two patients discontinued the drug due to adverse events possibly related to it. The rest of the patients completed the treatment with dalbavancin, with a median duration of 56 days (IQR 17.5, 115.5). All achieved complete resolution and present no relapse after a median follow-up of 9.9 months (IQR 4.8, 16.6).
CONCLUSIONS: Dalbavancin was a safe, effective and convenient alternative in selected paediatric patients with complicated non-ABSSSI infections caused by Gram-positive bacteria.
Experimental: After obtaining informed consent, 100 patients with bipolar I, or II disorders and alcohol abuse/dependence confirmed by a structured clinical interview (SCID) will be enrolled. from referral sources in the community we have developed over the past 3 years. A medical history and physical examination, including an eye exam with an ophthalmoscope, will also be performed at baseline to rule out serious medical illnesses and cataracts. Baseline labs including a liver panel and CBC will be obtained. Women of child-bearing potential will be given a urine pregnancy test. Baseline measures of psychiatric symptoms will be assessed with the HRSD, YMRS, and Barratt Impulsiveness Scale. Alcohol cravings will be assessed with the Obsessive Compulsive Drinking Scale (OCDS). Alcohol use including number of drinks/2 weeks, days used in the past two weeks, and days of heavy use will be obtained as will a urine drug/alcohol screen. Alcohol use and cravings will also be recorded throughout the study. Side-effects will be assessed with a general side effects scale, the Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale (SAS), and Barnes Akathesia Rating Scale (BARS). GGT levels will also be repeated at weeks 6 and 12. The subjects will be randomized and receive quetiapine or identical appearing placebo add-on therapy in a double-blind fashion for 12 weeks. Subjects will return every two weeks for reevaluation with the above outcome measures and for upward titration of study drug. All subjects will be given the option of receiving open-label quetiapine for an additional 4 weeks (with continuing assessment of mood and alcohol use/cravings every 2 weeks) at the end of the study or discontinuing medication.
The invention relates to a method for preparing asaryl sub-micro-emulsion, which comprises that dissolving the insoluble drug asaryl into oil, adding emulsifier, auxiliary emulsifying agent and other additives, to prepare the water-coat-oil sub-micro-emulsion. The sub-micro-emulsion carrier can improve the solubility of asaryl, to obtain uniform liquid agent. And the diameter of sub-micro-emulsion is lower than 500nm, which will not accumulated and laminate at room temperature in two years, with stable quality. The invention can be made into injection, atomization agent or nasal feeding agent, with high effect than oral agent. And the invention can avoid organic solvent and towen dissolvent to improve safety. The inventive asaryl sub-micro-emulsion can be used to treat bronchial asthma, or the like.
A waterborne composition for application to fingernails and toenails includes an emulsified resin binder, coalescents, colored pigments, and additives. In a preferred embodiment, the emulsified resin binder is a phenyl ethylene-acrylic copolymer which is available in many different glass transition temperatures (Tg°c.=30° to 100°), each of which have different physical and chemical properties. The formulas for each specific Tg°c. vary in the types of polyol blends of acrylic copolymers. Although other values of Tg°c. may produce fair results, it was found that good results were obtained when a blend of Tg°c.=25 or lower (for flexibility) and Tg°c.=40 or higher (for hardness) were used.